| abstract |
This disclosure relates to the discovery of a novel family of small molecule inhibitors of "first in class" HBV covalent closed loop (ccc) DNA for use as therapeutic agents in the management of chronic hepatitis B virus (HBV) . An agent is provided that provides an inhibitor of the histone deacetylase activity that mediates subsequent modification of cccDNA, histone modifier, and eventually HBV cccDNA, which has never been achieved by pharmaceutical agonists. Also provided are methods of modulating HBV cccDNA, methods of treating or preventing HBV in a subject, and methods of modulating cccDNA transcription of hepatitis B in a subject. |